FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891727106> ?p ?o ?g. }

• W2891727106 abstract "e14583 Background: Cancer research has been criticized regarding the generalizability of trials to older persons, as well as the timeliness of the impact of new trials on real-world practice. Despite growing enthusiasm about programmed death 1 checkpoint inhibitors (anti-PD1s), little is known about the speed with which these drugs are adopted into real-world practice, or whether anti-PD1 treated patients in real-world practice are older than patients treated in trials. Methods: We used retrospective data from Flatiron Health’s electronic health record database, which includes 250 cancer clinics and 1.5 million patients with cancer. We identified patients diagnosed after January 1, 2011 who underwent systemic therapy for: advanced melanoma (n=1,670), advanced non-small cell lung cancer (aNSCLC; n=19,536), or metastatic renal cell carcinoma (mRCC; n=2,018). Then, we determined the proportion treated with anti-PD1s in the 2 nd line or later following US Food and Drug Administration (FDA) approval. Therapy lines containing study drugs were excluded. Chi-square tests were used to compare age distributions of patients treated in real-world practice to patients treated in trials that support FDA approval. Results: At 6 months following FDA approval, 71.9% of patients with melanoma undergoing treatment were receiving anti-PD1s, versus 33.0% of patients with aNSCLC and 46.0% of patients with mRCC. Within 1 year, more than half of all treated patients with these 3 cancers were receiving anti-PD1s (71.0% in melanoma; 51.4% in aNSCLC; and 51.8% in mRCC). The median ages at first receipt of anti-PD1s were ≥65 years (65.1 years in melanoma; 67.9 years in aNSCLC; 66.0 years in mRCC). Anti-PD1 treated patients were significantly older in real-world practice than patients treated in trials (Table: all p<0.001). Conclusions: In a large national sample of patients with cancer, anti-PD1s were adopted rapidly into real-world practice. Compared to patients treated in real-world practice, older patients were underrepresented in clinical trials. [Table: see text]" @default.
• W2891727106 created "2018-09-27" @default.
• W2891727106 creator A5006468163 @default.
• W2891727106 creator A5015481262 @default.
• W2891727106 creator A5027148722 @default.
• W2891727106 creator A5031832642 @default.
• W2891727106 creator A5032284029 @default.
• W2891727106 creator A5044057699 @default.
• W2891727106 creator A5047725888 @default.
• W2891727106 creator A5055018385 @default.
• W2891727106 creator A5056566014 @default.
• W2891727106 creator A5058673346 @default.
• W2891727106 creator A5073288035 @default.
• W2891727106 creator A5075569504 @default.
• W2891727106 creator A5078289544 @default.
• W2891727106 creator A5089179189 @default.
• W2891727106 date "2017-05-20" @default.
• W2891727106 modified "2023-09-26" @default.
• W2891727106 title "Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors." @default.
• W2891727106 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14583" @default.
• W2891727106 hasPublicationYear "2017" @default.
• W2891727106 type Work @default.
• W2891727106 sameAs 2891727106 @default.
• W2891727106 citedByCount "1" @default.
• W2891727106 countsByYear W28917271062019 @default.
• W2891727106 crossrefType "journal-article" @default.
• W2891727106 hasAuthorship W2891727106A5006468163 @default.
• W2891727106 hasAuthorship W2891727106A5015481262 @default.
• W2891727106 hasAuthorship W2891727106A5027148722 @default.
• W2891727106 hasAuthorship W2891727106A5031832642 @default.
• W2891727106 hasAuthorship W2891727106A5032284029 @default.
• W2891727106 hasAuthorship W2891727106A5044057699 @default.
• W2891727106 hasAuthorship W2891727106A5047725888 @default.
• W2891727106 hasAuthorship W2891727106A5055018385 @default.
• W2891727106 hasAuthorship W2891727106A5056566014 @default.
• W2891727106 hasAuthorship W2891727106A5058673346 @default.
• W2891727106 hasAuthorship W2891727106A5073288035 @default.
• W2891727106 hasAuthorship W2891727106A5075569504 @default.
• W2891727106 hasAuthorship W2891727106A5078289544 @default.
• W2891727106 hasAuthorship W2891727106A5089179189 @default.
• W2891727106 hasConcept C121608353 @default.
• W2891727106 hasConcept C126322002 @default.
• W2891727106 hasConcept C177713679 @default.
• W2891727106 hasConcept C2777701055 @default.
• W2891727106 hasConcept C2780057760 @default.
• W2891727106 hasConcept C2780674031 @default.
• W2891727106 hasConcept C71924100 @default.
• W2891727106 hasConceptScore W2891727106C121608353 @default.
• W2891727106 hasConceptScore W2891727106C126322002 @default.
• W2891727106 hasConceptScore W2891727106C177713679 @default.
• W2891727106 hasConceptScore W2891727106C2777701055 @default.
• W2891727106 hasConceptScore W2891727106C2780057760 @default.
• W2891727106 hasConceptScore W2891727106C2780674031 @default.
• W2891727106 hasConceptScore W2891727106C71924100 @default.
• W2891727106 hasLocation W28917271061 @default.
• W2891727106 hasOpenAccess W2891727106 @default.
• W2891727106 hasPrimaryLocation W28917271061 @default.
• W2891727106 hasRelatedWork W1971870468 @default.
• W2891727106 hasRelatedWork W1986365151 @default.
• W2891727106 hasRelatedWork W2043024769 @default.
• W2891727106 hasRelatedWork W2045026357 @default.
• W2891727106 hasRelatedWork W2142959209 @default.
• W2891727106 hasRelatedWork W2162380243 @default.
• W2891727106 hasRelatedWork W2176347377 @default.
• W2891727106 hasRelatedWork W2326074527 @default.
• W2891727106 hasRelatedWork W2619692170 @default.
• W2891727106 hasRelatedWork W2751257824 @default.
• W2891727106 hasRelatedWork W2884880012 @default.
• W2891727106 hasRelatedWork W2968560640 @default.
• W2891727106 hasRelatedWork W2998826586 @default.
• W2891727106 hasRelatedWork W3003670850 @default.
• W2891727106 hasRelatedWork W3006968198 @default.
• W2891727106 hasRelatedWork W3081192353 @default.
• W2891727106 hasRelatedWork W3088761592 @default.
• W2891727106 hasRelatedWork W3136465602 @default.
• W2891727106 hasRelatedWork W3154528253 @default.
• W2891727106 hasRelatedWork W3206121183 @default.
• W2891727106 isParatext "false" @default.
• W2891727106 isRetracted "false" @default.
• W2891727106 magId "2891727106" @default.
• W2891727106 workType "article" @default.